Fenofibrate is a cholesterol-lowering medication that belongs to the class of lipid-modifying agents. It is available in pill form with strengths of 160 mg and 200 mg. In Hong Kong, fenofibrate is a prescription (Rx) drug regulated by the Department of Health. The medication is used primarily to improve abnormal blood lipid levels, especially high triglycerides.
Fenofibrate activates a nuclear receptor called peroxisome proliferator-activated receptor-α (PPAR-α).
Fenofibrate is approved by Hong Kong’s health authorities for the following indications:
Typical patients are adults with documented lipid abnormalities who require additional risk reduction for cardiovascular disease.
Fenofibrate has been studied for several off-label applications, though these are not approved by Hong Kong regulatory agencies:
Off-label use requires medical supervision and individualized risk assessment.
Patients with any of these conditions should discuss alternatives with their healthcare provider.
If a patient is taking multiple medications, they should inform their clinician of all prescription drugs, over-the-counter products, and herbal supplements.
Regular follow-up with a healthcare professional ensures optimal lipid control and early detection of adverse effects.
This article provides educational information about fenofibrate and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Fenofibrate can be combined with statins to achieve greater reductions in triglycerides and modest improvements in HDL-cholesterol. However, the combination raises the risk of muscle toxicity, so clinicians usually monitor creatine kinase levels and may choose a lower-intensity statin.
Take the missed pill with the next main meal, regardless of the new local time. Avoid taking two doses at once to prevent excess exposure.
Fenofibrate has a neutral or slightly beneficial effect on fasting glucose in many patients with type 2 diabetes, but it is not a glucose-lowering agent. Diabetes management should continue with appropriate antidiabetic medications.
Rarely, patients report blurred vision or visual disturbances, usually linked to changes in blood lipids. Report any persistent visual symptoms to a healthcare professional promptly.
Both are fibrates that activate PPAR-α, but fenofibrate has higher potency and longer half-life, allowing once-daily dosing. Bezafibrate may require multiple daily doses and has a slightly different safety profile.
Fenofibrate’s absorption is enhanced by fatty meals, not by grapefruit juice. Grapefruit does not significantly affect its metabolism, so no special restriction is needed.
Fenofibrate is contraindicated in active severe liver disease. If you have any liver injury, inform your clinician before starting the drug; alternative lipid-lowering agents may be recommended.
Fenofibrate has not been directly linked to kidney stone formation. However, patients with chronic kidney disease should have renal function monitored regularly.
Prescription medications in Hong Kong are typically covered under private or public health schemes after a clinician’s prescription. Check with your insurer about specific coverage requirements.
It is best to keep fenofibrate in a cool, dry place away from humidity. A bathroom cabinet may be too humid; store the medication in a bedroom drawer or a dedicated medication box instead.
